- Home
- TEI vs DRTS Comparison
TEI vs DRTS Comparison
Compare TEI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | DRTS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.6M | 300.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TEI | DRTS |
|---|---|---|
| Price | $6.36 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 142.4K | ★ 159.0K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $2.30 |
| 52 Week High | $5.39 | $5.10 |
Technical Indicators
Market Signals| Indicator | TEI | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 71.25 |
| Support Level | $6.55 | $3.84 |
| Resistance Level | $6.65 | $5.07 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 20.93 | 92.16 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.